GlassScriptPhysician profile
Birgit M Wiswe
NPI 1376515122
$12,661.00
in general payments reported to CMS, 2019-2025
68 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $1,191 · 2021: $1,906 · 2022: $2,104 · 2023: $2,199 · 2024: $2,046 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,001 · Education: $15.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,000.95 |
| Education | $15.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,513.65 | 2019-2025 | Qulipta, Vraylar, Synthroid |
| Novo Nordisk INC | $1,377.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,053.22 | 2019-2025 | |
| Lilly USA, LLC | $929.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $694.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $681.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $405.52 | 2021-2025 | |
| Axsome Therapeutics, INC. | $364.92 | 2023-2025 | Sunosi, Symbravo, Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.54 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $326.37 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $302.84 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $287.64 | 2019-2025 | |
| Harmony Biosciences LLC | $286.97 | 2022-2024 | Wakix |
| Otsuka America Pharmaceutical, INC. | $264.45 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbott Laboratories | $244.37 | 2021-2025 | Freestyle Libre 3 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birgit Wiswe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.